Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01834261 · ClinicalTrials.gov registry record · Phase 1

Brain Dynamics of Oxytocin

A Phase 1 study of Brain Dynamics in Healthy Adults, sponsored by Stony Brook University.

Completed
Registry status
Phase 1
Development phase
51
Enrollment target
3
Study locations

NCT01834261: Completed Phase 1 study of Brain Dynamics in Healthy Adults, sponsored by Stony Brook University.

NCT01834261 is a Phase 1 study of Brain Dynamics in Healthy Adults that has completed, run by Stony Brook University. The registered enrollment target is 51 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01834261, a Phase 1 study of Brain Dynamics in Healthy Adults, has completed, sponsored by Stony Brook University.

COMPLETED
Registry status
Phase 1
Development phase
51 participants
Enrollment target
3
Study locations

Study Summary

Oxytocin is a neuropeptide that is well known for its role in social and affiliative behavior in humans. Oxytocin receptors are significantly lowered in autistic individuals and administration of oxytocin has shown benefits in enhancing social recognition and behavior in autistic children. However, more recent research has refined the behavioral effects of oxytocin, moving away from the notion that the neuropeptide blindly induces love and trust, towards the view that it actually increases social perception in assessing friend vs. foe: supporting cohesion with 'insiders' and distrust and aggression for 'outsiders.' Oxytocin is responsible for the selective aggression shown by lactating female mammals protecting their young, an effect demonstrated also in humans, and has been shown to strengthen feelings of ethnocentrism. However, no neuroimaging study to date has investigated this effect, with the consequence that its neurobiological basis is still unknown. The general aim of our study is to determine meso-circuit brain dynamics that underlie oxytocin's amplification of both trust and aggression; and specifically, using neuroimaging (fMRI, magnetoencephalography, and behavioral testing) whether oxytocin amplifies kinship bias by attenuating social reward learning.

Primary Outcome

This study recruited healthy adults. Subjects participated in an interactive neuroeconomic game, an iterative version of the classical "Trust Study." During this game, the subject ('investor') is first provided a sum of money (20 units). He then has the choice in terms of how much to invest in a fictional computer-generated trustee. The trustee then sends some percentage back to the subject ('investor'), and the game iterates over 20 trials (rounds). We computed the investment ratio as the ratio

Interventions

  • DRUG Syntocinon Nasal Spray, 40IU
  • DRUG Syntocinon Placebo Formulation, 40IU

Study Locations (3)

Massachusetts

  • Martinos Imaging Center at the McGovern Institute for Brain Research at MIT - Cambridge
  • Martinos Center for Biomedical Research, Building 149, 13th Street - Charlestown

New York

  • Bioengineering Building , Stony Brook University - Stony Brook

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2013-04
Est. Completion 2015-05
Phase Phase 1
Stony Brook University

127 total trials

What the finished NCT01834261 record still lists

NCT01834261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% lower).

The record links to 1 condition, with Brain Dynamics in Healthy Adults appearing as the primary indexed condition, and to 2 interventions - of which Syntocinon Nasal Spray, 40IU is the first listed.

NCT01834261 reports a single indexed study location in Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT01834261 about?

NCT01834261 is a clinical study titled "Brain Dynamics of Oxytocin". Oxytocin is a neuropeptide that is well known for its role in social and affiliative behavior in humans. Oxytocin receptors are significantly lowered in autistic individuals and administration of oxytocin has shown benefits in enhancing social recognition and behavior in autistic children. However, ...

What is the current status of trial NCT01834261?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2013-04. Estimated completion is 2015-05.

What conditions does trial NCT01834261 study?

This clinical trial studies the following conditions: Brain Dynamics in Healthy Adults.

What interventions are being tested in trial NCT01834261?

The interventions under investigation include: Syntocinon Nasal Spray, 40IU (DRUG), Syntocinon Placebo Formulation, 40IU (DRUG).

Who is sponsoring clinical trial NCT01834261?

This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01834261 being conducted?

This trial has 3 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT01834261's enrollment target sits among peer trials

51 969th of 2000 higher than 1,028 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02701153 · 51 participants · NA

    Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

  • NCT03663790 · 51 participants · NA

    Effects of Gait Retraining on Lower Extremity Biomechanics

  • NCT03874052 · 51 participants · Phase 1

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • NCT04704661 · 51 participants · Phase 1

    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01834261, the US trial registry maintained by the National Library of Medicine. NCT01834261 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.